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Detection & Identification of Infectious Agents (DIIA) Innovation 
Platform: Health Econometrics 
 
Area: Tuberculosis (TB) 
 
 
1  Background 
 
A number of clinical/disease areas have been prioritised by the TSB and DH for the DIIA 
Innovation Platform.  To support commissioning of technology developments in the area of 
tuberculosis detection in humans, a scoping review has been undertaken to help identify the specific 
requirements for new diagnostic test development and likely payback in the area of point of care 
(POC) tuberculosis tests in the UK. 
 
There has been a gradual rise in the number of tuberculosis (TB) cases observed in the UK over the 
last 20 years, with a 4.2% rise in 2009 giving an overall 9,040 TB cases diagnosed or 15 cases per 
100,000 population [1]. 
 
The aims of this economic review are to identify available information on the following for 
tuberculosis (TB): 
 
 economic burden of disease in the UK;  
 current NHS cost of TB detection and cost of treating identified TB cases;  
 evidence on cost-effectiveness of current tests for detection of active and latent TB 
infection; and 
 estimates of the economic benefits which new POC tests might provide in the UK. 
 
The following sections present an analysis of the four areas above.  Cost figures are inflated to 2009 
prices. 
 
 
2  Economic burden of disease and cost of TB tests and treatment 
 
2.1 Economic burden of disease 
 
UK data on the economic burden associated with TB are incomplete.  We have therefore collected 
information through a literature review and contacting experts.  There were. 
 
2.1.1  TB mortality: 
Identifying the costs associated with TB mortality is complex.  The Health Protection Agency 
(HPA) enhanced surveillance schemes (Enhanced Tuberculosis Surveillance (ETS) in England, 
Wales and N Ireland and Enhanced Surveillance of Mycobacterial Infections (ESMI) in Scotland) 
provide an estimate of UK mortality.  Twelve month follow up by ETS/ESMI of TB cases identified 
168 deaths in 2009 where TB caused or contributed directly to death [1]. 
 
It has been suggested these figures may underestimate deaths associated with TB for a number of 
reasons.  Firstly, outcome information was not reported in 3.1% of cases.  Also, although 474 
patients were reported to have died in the UK in 2009 [2], only 268 reports included information 
which clarified the cause of death; of these, 168/268 were directly linked to TB. 
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An alternative source of information is the Office for National Statistics (ONS) notifications of 
infectious disease deaths, classified according to the International Classification of Disease coding 
system (ICD10) [3].  ONS identifies all deaths where TB is reported to be the underlying cause of 
death, but only for England and Wales only [4].  
 
For the UK, using HPA mortality figures, the number of life years (LYs) and Quality Adjusted Life 
years (QALYs) lost can be calculated as follows.  Based on an estimated median age at death from 
TB in the UK of 64 years [3, 5] combined with a reported life expectancy in the UK for 2009 of 
80.1 years [6], 474 deaths reported by the HPA in 2009 would equal ~7,630 Life Years (LYs) lost.  
After discounting at 3.5%, weighting by quality of life (0.75 for people in this age group [7]), and 
valuing an additional life year at £30k [8], this produces a total mortality cost of approximately 
£99.0 million per annum for the UK.  Some of this mortality burden might be prevented through 
more efficient TB diagnosis. 
 
2.1.2  TB morbidity: 
There is no published estimate of the UK morbidity burden associated with TB cases.  The health 
related quality of life (EQ-5D) for individuals with TB has been quantified as 0.726 [9].  Other 
publications report Quality of Life (QoL) weights at 0.675 for patients starting on treatment and 
0.813 for patients 2 months into treatment [10].  For the purpose of this analysis we assumed a QoL 
weight of 0.7.  Based on this figure and the fact that non-fatal tuberculosis lasts for about six 
months [9], it is possible to estimate that approximately 1,356 QALYs were lost due to morbidity 
associated with the 9,040 TB cases reported in 2009 [1].  This assumes that an individual’s quality 
of life is affected for the six months during which treatment is provided [11, 12], and then returns to 
full health.  This figure can be converted to a morbidity cost of approximately £40.7 million per 
annum in the UK (assuming a life year is valued at £30k, no discount rate applied).  Once again, 
some of this morbidity burden might be preventable through earlier and more efficient diagnosis. 
 
2.1.3  Costs to society: 
An estimate of the total cost to society associated with TB is not available for the UK.  However, in 
Germany the total cost of an adult with TB, including productivity loss/sick benefit, is estimated at 
€11,240 (£8,654 at 2009 prices) [13].  Based on the number of cases identified in the UK in 2009 
(9,040), and assuming a similar demographic (i.e. working age), this would translate to a UK cost of 
approximately £78.0 million per annum. 
 
2.1.4 Total economic burden of disease 
Totalling the separate costs above for mortality, morbidity and societal costs produces a UK figure 
of approximately £584 million per annum or £94, 510 per 100,000 population
1
. 
 
 
2.2 Cost of treating TB 
 
In this section we attempt to quantify the various healthcare costs associated with TB cases (active 
and latent infections) once diagnosed.  All assumptions are stated.  A more complete description of 
the calculations is given in the Annex 1. 
 
2.2.1  Standard TB drug therapy: 
A 2007 HTA review reported an annual drug costs for TB of £1.95 million/year in 2002 prices 
[11].  Updated to net present value [14] this would represent £2.3 million per annum (2009 
prices).  A more accurate cost figure can be calculated based on the number of cases (9,040) 
diagnosed in 2009 [1], mean standard drug therapy costs (excluding multi-drug resistant TB) per 
patient over 6 months, and the cost of drug administration. 
 
                                            
1
 Office for National Statistics (ONS) number of people in the UK 61,792,000 in mid-2009 
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Standard drugs can be administered in clinics or, for more difficult cases, through intensive 
supervised support, termed Directly Observed Therapy (DOT).  For cases requiring DOT, the cost 
of delivery has been estimated at £2,964 per ‘hard to reach’ (HTR) patient and £300 per ‘not hard to 
reach’ patient in the UK [15].  Although national figures on the number of DOT cases are not 
available, data from Greater Manchester indicate that 5.5% (19/345) of patients were managed in 
this way in 2004
2
; and a similar figure of approximately 5% has been provided from Liverpool
3
.  
Experts acknowledge that the percentage is likely to be higher in London.  More recently, the HPA 
has reported that social risk factors exist for at least 10% of TB cases [2], and that data show that 
42% of cases with at least one social risk factor are started on DOT [2].  In addition, HPA economic 
modelling assumes that 10% of the ‘not hard to reach’ population will complete DOT [15].  We 
have assumed that 4.2% of all TB patients (380) will fall into the expensive HTR group for DOT 
therapy (£2,964 per patient) and that a further 9% of cases (814) will require less expensive DOT 
administration (£300 per case).  Excluding MDR cases (see below) this will leave 7,788 patients 
who receive standard treatment. 
 
For the estimated 1,194 TB patients who had their drugs administered through DOT, and the unit 
costs above for DOT, intensive therapy support for UK cases in 2009 would be £1.1 million for the 
HTR population and £0.21 million for the remaining ‘not hard to reach’ population. This produces a 
grand total of approximately £1.37 million per annum for drug costs and their DOT 
administration. 
 
The remaining 7,788 patients who received standard therapy in 2009 would incur approximately 
£1.63 million per annum for standard drug and administration costs (2009 prices) based on a 
mean drug therapy cost per patient over 6 months of £181.47 in 2003 prices [11] or £210 per case 
(2009 prices).  The total (£3.0 million)  
 
2.2.2  Multi-drug resistant (MDR) TB drug therapy: 
Multi-drug resistant TB is an important issue worldwide, with increasing rates reported and new 
drugs being developed [16, 17].  The current cost of drugs alone for treating the average patient is 
estimated to be 50 to 200 times higher than for treating a drug-susceptible TB patient, with the 
overall costs of care 10 times higher or more [18]. 
 
For the relatively small number of UK patients whose TB is multi-drug resistant the mean cost of 
managing a patient with pulmonary MDR TB is reported at £60,000 in 2000 prices (£75,510 in 
2009 prices) [19].  This figure is consistent with the data from the 2011 NICE clinical guideline  
[12].  Based on this price and 58 cases reported in the UK in 2009 [1], the total cost of managing 
MDR cases is estimated at approximately £4.38 million per annum.  
 
2.2.3  Inpatient episodes: 
Inpatient care costs are difficult to estimate for TB.  Based on 2,426 finished consultant episodes 
recorded in 2002 at a mean cost of £2,219 each (£2,652 in 2009 prices) [11], UK costs associated 
with non-elective pulmonary admissions and pleural TB cases were estimated to be £6.4 million.  
This figure may overestimate TB costs because it does not allow for the influence of co-morbidities 
(e.g. 4.9% of TB cases were co-infected with HIV in 2010 [2]).  On the other hand, it may 
underestimate true costs since this figure excludes elective pulmonary TB admissions and all extra-
pulmonary TB cases.  If elective mean inpatient care costs are assumed to be similar to non-elective 
admission costs, the total inpatient cost estimate would rise to £9.6 million.  Or, using a base case 
cost estimate of £3,457 per non-elective episode reported elsewhere [20] and levels of emergency 
admissions assumed in the 2006 NICE report, a higher figure of £15.4 million (2009 prices) is 
obtained.  Both these figures still exclude extra-pulmonary TB cases; 53% of TB cases had extra-
pulmonary disease only in 2010 [1]. 
 
                                            
2 Personal communication, Dr Marko Petrovic, HPA 
3 Personal communication, Dr Peter Ormerod, Liverpool 
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The most recent HPA report for NICE [2] adopts a different approach which produces a somewhat 
higher figure.  Based on this approach, HTR patients are said to incur hospitalisation costs of £7,320 
and non-HTR patients a hospitalisation cost of £3,386.  According to HES data, 56% of TB patients 
are hospitalised [21].  HPA estimates that HTR TB patients represent 10% of the TB patient 
population.  Using these figures, we estimate that in 2009 the UK inpatient costs for TB patients 
would have amounted to approximately £19.0 million per annum. 
 
2.2.4  Primary Care/ Outpatients: 
In addition to inpatient care, individuals diagnosed with TB will also require outpatient visits and 
GP consultations.  For the purpose of the present analysis, costs of £921 [15] are applied to both 
hospitalised and non-hospitalised populations.  If it is assumed that about 90% of all active TB 
cases will comply with appointments, the total cost of primary and outpatient care is estimated at 
approximately £7.60 million per annum. 
 
2.2.5  Prophylaxis: 
The Health Protection Agency’s systems of notification and enhanced surveillance do not collect 
data on cases of latent TB infection (LTBI), or on the number of people screened and given 
preventive treatment.  This consists of isoniazid prescribed over 3 months.  The total isoniazid cost 
for 2007 was reported as £604,181 (£631,101 per annum at 2009 prices) [11].  However, there is no 
estimate of the cost of administering prophylaxis.  We estimate the total cost of latent TB treatment 
for the 17,040 Tuberculin Skin Test positive cases identified annually (see Annex 1) at a unit cost of 
£647per LTBI [22] as approximately £11.0 million per annum. 
 
2.2.6  Summary of cost for TB treatment: 
Based on the figures presented above, the total cost of treatment for TB cases in the UK is estimated 
at approximately £45.0 million per annum (2009 prices).  This represents £72,825 per 100,000 
general population.  Excluding LTBI and MDR costs, other TB cases are estimated to cost 
approximately £3,300 each. 
 
 
2.3 Cost of diagnostic services for TB 
 
In this section we attempt to quantify the resources used to diagnose patients with suspected active 
TB and to identify whether any of their contacts have active or latent TB.  Once again, any 
assumptions made are stated.  A more complete description of the calculations is given in the 
Annex 1. 
 
2.3.1  Numbers tested: 
Because the incidence of TB in patients referred with suspected active TB is not routinely recorded 
in the UK it is difficult to accurately quantify the number of people tested annually.  However, a 
long-term study in Leicester & Rutland (over the period 2005-8) documented the proportion of 
active TB cases in all GP referrals for chest X-rays for suspected TB as 36%.
4
  A similar figure 
(between 25% and 33% of suspects referred) was independently reported, based on expert opinion, 
in London
5
.  The ratio is likely to be smaller in other parts of the country with a lower incidence of 
TB, so we assumed an incidence of less than one in four referrals.  Based on this figure, and the 
number of cases diagnosed in 2009, we estimated a crude figure of approximately 35,200 diagnostic 
referrals made for suspected TB.  This figure excludes screening tests and contacts testing. 
 
For the latter, it has been reported that there are an average of 6.5 contacts tested per primary case 
[23], of which 1% will have active TB [12].  Addition of contact tracing tests to diagnostic referrals 
produces a UK figure of approximately 90,000 patients being tested for suspected TB or screened as 
contacts annually.  This excludes people who might be screened at port of entry or in prisons, 
                                            
4 Personal communication, Dr Gerrit Woltmann, Leicester 
5 Personal communication, Dr Graham Bothamley, Homerton Hospital NHS Trust, London 
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hostels for the homeless or new entrant clinics.  The HPA economic model developed for NICE 
estimates that 10,000 homeless people and 10,000 prisoners could be screened annually by mobile 
X-ray units [15].  Inclusion of all these cases indicates that over 110,000 people are tested or 
screened annually in the UK (excluding port of entry screening of immigrants and refugees – see 
section 3.3). 
 
2.3.2  Cost of chest X-rays: 
The unit cost for outpatient chest X-rays is £28 (NHS reference cost); for mobile X-ray the cost is 
£16 [15].  The number of X-rays performed annually in UK hospitals for suspected TB cannot be 
directly identified.  Radiology departments do not record these
6
.  Similarly, GP practice records do 
not consistently distinguish X-rays requested because there is some suspicion of TB
7
.  If it is 
assumed that symptomatic patients being referred for suspected TB (approximately 35,200) all 
undergo a chest X-ray as advised [12], the cost would equal £0.99 million per annum.  If, in 
addition, 20,000 homeless/prisoners are screened annually using mobile X-ray, the added cost 
would be £0.32 million per annum, giving a total cost for chest X-rays of approximately £1.31 
million per annum (this excludes port of entry screening). 
 
2.3.3  Cost of laboratory tests: 
Unit test costs for the most common laboratory tests were identified through a literature search and 
are shown in Table 1.  The figures presented should be treated with some caution because full 
laboratory-based costs are not usually reported.  Articles vary in terms of whether all key elements 
are included (i.e. particularly staff, capital equipment, accommodation and overheads); and certain 
costs associated with laboratory testing are generally excluded e.g. sample collection, transport, 
results reporting [24]. 
 
National laboratory TB test costs are difficult to estimate because laboratory testing protocols 
involve the use of sequential tests and assumptions have to be made about the numbers of referrals 
at each stage.  For suspected TB cases (~35,200 referrals per annum), we assumed that GPs will 
provide three laboratory samples as advised [12], and that all three samples will have a sputum 
smear (microscopy) test (£1.5per sample) plus liquid culture (£27.16 each).  Also, that at least one 
sample will undergo standard solid culture (£16.7) and that each person will have a NAAT test or 
gene probe MTBC (£15.67) [11].  In addition, we assumed that the 9,040 positive cases identified 
will undergo a further test to screen for antibiotic susceptibility (~£70 per case) [25].  This produces 
a total cost of laboratory testing for suspected TB of approximately £4.44 million per annum. 
 
In addition, if we assume two primary care consultations are linked to this process, one as part of 
the test referral process and one for communicating the result (at £36 each [26]), primary care costs 
linked to suspected TB cases will total approximately £2.52 million per annum.   
 
2.3.4  Cost of contact tracing and testing: 
The cost for tracing contacts of patients diagnosed with TB has been estimated by Eralp et al as £23 
per contact [22].  This covers the cost of tracing people and telephone contact, but excludes the 
subsequent cost of any tests and treatment.  For the 9,040 TB cases identified in 2009, based on 6.5 
contacts traced per index case, the UK cost of contact tracing is approximately £1.35 million per 
annum. 
 
In order to calculate the cost of testing contacts, for the purpose of this cost analysis it was assumed 
that all contacts of active cases (ca 58,760 based on 6.5 contacts per case) will be tested for latent TB 
infection as per procedures recommended in the NICE guideline [12].  We assumed that this first 
involves a Tuberculin Skin Test (TST) or Mantoux test; and that 30% of these will be positive [27] 
and will then undergo the Interferon-Gamma Test (IGT).  The total cost of testing contacts in 
2009 is therefore estimated at approximately an additional £1.85 million (see Annex 1). 
                                            
6 Personal communication, Dr Richard Wellings, Radiology Department, UHCW Trust, Coventry 
7 Personal communication, Dr Tim Holt, Assoc Prof General Practice, Warwick Medical School 
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2.3.5  Total diagnostic service costs: 
Based on the estimates above, the resources used to identify patients with TB in the UK (including 
contact tracing) total of approximately £11.47 million per annum (2009 prices).  This represents 
£18,560 per 100,000 general population.  This figure excludes the national cost of the Health 
Protection Agency’s systems for disease notification and surveillance. 
 
 
2.4 Total cost of UK TB detection and treatment 
 
Totalling the separate costs estimated above for treatment and tests produces a UK figure of £56.47 
million per annum or £91,390 per 100,000 population.  Alternatively, a crude cost per case can be 
estimated based on global prices reported by the HPA (£15,000 for a hard to reach case and £4,606 
for other cases) [15].  When applied to the 9,040 cases detected in 2009, this would provide a 
weighted average of £5,645 per case and indicate a slightly lower figure of approximately £51.0 
million per annum. 
 
 
2.5  Conclusions: Economic burden of disease & TB diagnosis and treatment costs 
 
 In terms of mortality, the annual TB burden in the UK is estimated to be 7,630 Life Years 
lost.  This equates to an estimated mortality cost of £99.0 million per annum. 
 
 In terms of morbidity, the estimated annual burden of disease in the UK is 1,355 QALYs 
lost for cases diagnosed in 2009.  This equates to an estimated morbidity cost of £40.7 
million per annum. 
 
 Although the total cost to society associated with TB is not available for the UK; a rough 
annual figure of £78.0 million (to include productivity loss) can be estimated based on 
international data. 
 
 TB treatment, including drugs for active TB, MDR cases and prophylaxis (and their 
administration), hospital inpatient episodes, outpatient visits and primary care consultations 
are estimated to total at £45.0 million per annum in the UK.  Within this figure, the annual 
cost of treating MDR cases is estimated to be £4.38 million. 
 
 The cost for diagnosis of TB in the UK is in the region of £11.47 million per annum, 
including contact tracing and testing for latent TB infection.  There is a high level of 
uncertainty around the unit cost of tests currently used in the NHS.  The number of patients 
being tested annually in the UK for suspected TB is estimated to be in the order of 35,200.  
Inclusion of contact tracing raises this figure to ~90,000 people.  A further 20,000 homeless 
people and prisoners screened would raise the total to 110,000; screening at port of entry 
would add to this figure even further. 
 
 In terms of mortality and morbidity, the UK economic burden for TB is modest compared 
to countries in the developing world.  UK expenditure on TB treatment and diagnosis, 
which is roughly estimated at £91,390 per 100,000 population, is significantly lower than 
the figure reported from the USA of $US 700 million/year [28], equivalent to a net present 
value of ~£194,000 per 100,000 population. 
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3  Evidence on cost-effectiveness of current TB tests 
 
Ideally, the value for money (cost-effectiveness) any new POC test should be compared to that of 
current TB tests.  However, from our review of the literature, published articles assessing the 
various tests currently available are inconsistent in the way that results are presented and of varying 
quality.  Reported cost-effectiveness will not only be sensitive to factors such as technical 
performance (sensitivity/ specificity) and test cost, but also demographics of the population tested 
and the testing strategy used (e.g. testing high-risk individuals versus testing a whole population) 
[29].  This is rarely reported.  For more rapid tests, as well as speed of test result and impact on TB 
transmission, cost-effectiveness will also be affected by any impact on associated services (e.g. 
other tests, hospitalisation rates etc) and the effectiveness of available treatment interventions, plus 
the comparator test or ‘status quo’ chosen [30].  These are rarely all reported in the articles 
identified.  Finally, an economic evaluation should ideally report cost-utility (e.g. cost per QALY).  
Ratios such as the cost per active case detected and treated or the cost per case detected are less 
useful for policy makers. 
 
 
3.1 Evidence on cost-effectiveness of tests currently used for active TB infections 
 
The review of the literature found relatively few studies which reported the cost-effectiveness of 
current TB tests listed in Table 1.  In the articles identified, economic results were usually 
presented in the form of a ‘cost per case detected’ (see Table 2).  Cost-utility analyses (i.e. cost/ 
QALY) were lacking. 
 
3.1.1  General evidence on cost-effectiveness of chest X-rays: 
Chest X-rays are reported to have a low sensitivity (67%) and specificity (61%) [15, 31].  
Therefore, although they can be used as a screen for TB, the reported cost per case detected is too 
high for them to be considered ‘cost-effective’.  For example, research in Canada has estimated a 
value of $CAD 9,898 per active TB case detected [30], equivalent to £5,863 (2009).  If treatment 
costs are included, this figure rises to £15,809 (2009) per active case detected and treated.  Thus, X-
rays appear not to be cost-effective as a diagnostic tool. 
 
It has been suggested instead that X-rays may be cost-effective when used to rule out pulmonary TB 
in a person who has a positive reaction to the TST but no symptoms of disease [23, 32].  However, 
the cost-effectiveness of such case-finding, for example using a mobile X-ray unit combined with 
enhanced case management interventions for homeless and imprisoned populations, is reported to 
be highly context-specific [15].  So a general statement about cost-effectiveness is not possible. 
 
3.1.2  Cost-effectiveness of chest X-rays vs. symptom checklists: 
The cost-effectiveness of a symptom checklist versus chest X-ray for initial screening for active 
disease depends on the relative accuracy of the two options and their costs.  Under base case 
assumptions, an economic modelling exercise indicates that screening by X-ray is more expensive 
although it may lead to an overall saving in NHS expenditure, due to a predicted lower number of 
false positive results [12]. 
 
3.1.3  Evidence on cost-effectiveness of current laboratory tests for TB detection: 
Although several articles purporting to assess tests currently available to detect active TB report that 
a test is ‘cost-effective’, the evidence to support this statement is usually limited.  Articles are 
generally of a poor quality and it is difficult to compare studies due to differences in the scope of 
the costs included and the types of outcomes measured.  None of the studies identified were of a 
quality to fully meet accepted HTA standards for reporting test performance [33].  Cost-
effectiveness, when quantified, was most commonly described in terms of the cost per case detected.  
The potential for comparison across studies was limited due to differences in the populations 
studied (particularly TB incidence) and the comparator used.  Because economic findings are highly 
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dependent on the clinical context and the economic perspective adopted in a study, differences in 
these made comparison across the studies identified difficult if not impossible.  As a result, even the 
most common measure of cost-effectiveness reported in the literature (i.e. cost per case detected) 
showed a very wide variation. 
 
Furthermore, most published studies focused on individual steps (tests) in the diagnostic process.  
The overall cost-effectiveness of the system-wide diagnostic pathway, including sequential tests, 
was usually not considered.  This represents an important gap in the evidence for current 
laboratory tests for TB detection 
 
Specific examples of ‘cost-effectiveness’ results are presented below.  These illustrate the 
variability in tests, method for reporting of cost-effectiveness, and the quality of findings.  This 
variability made any synthesis of the economic findings impossible: 
 
 Culture tests: the cost per active TB case detected is reported to be between $CAD 6,757 
(based on 1 specimen) and $CAD 17,284 (3 specimens) [30]. 
 TST: the cost per active TB case detected in Canada is estimated at $CAD 12,407 [30]. 
 PCR test: the cost per active TB case detected is reported to be $CAD 10,990 [30]. 
 PCR cross-blot hybridization: this is reported to cost $US 1.50/sample.  This cost is 
stated to be ‘more than offset’ by potential savings linked to earlier reporting [34]. 
 AMTD (Gen-Probe Inc): the testing strategy that incorporates dilution of smear-positive 
but not smear-negative respiratory specimens is simply reported to be ‘cost-effective’ [35]. 
 MMGIT, AMGIT CLJ and HLJ: the cost per case detected is ~US$ 95 when modelled 
for maximum throughput in Zambia.  When performed among smear-negative specimens, 
the cost per additional case identified is predicted to rise to US$ 487 for MMGIT, and to be 
even higher for other methods [36]. 
 INNO-LiPA Rif.TB PCR-based hybridization assay: this is simply reported to be ‘cost-
effective’ and highly reliable when run in parallel with a conventional TB laboratory 
diagnostic algorithm [37]. 
 RT-LAMP-ELISA-hybridization assay: this is reported to be more cost-effective than 
real-time TaqMan RT-PCR and AMTD assays [38]. 
 
Table 2 indicates the very wide range in cost per case values reported for various TB tests.  A range 
of £87 - £3,348 per case (£91- £3,497 in 2009 prices) was identified. 
 
3.1.4  Evidence on cost-effectiveness of tests for detecting multiple drug resistant (MDR) TB: 
 
Based on the most recent data, at least 7.1% of TB patients are resistant to at least one antibiotic [2].  
Drug resistant TB is important because patients who are sputum smear positive remain infectious 
for much longer than those with susceptible organisms.  MDR cases also have a higher mortality 
rate and they require more costly treatment with drugs of higher toxicity.  Once again, cost-
effectiveness was mainly reported in terms of the cost per case diagnosed; no cost-utility analyses 
were identified.  A number of individual studies did report the cost-effectiveness of tests for 
detection of MDR cases, but the lack of a systematic review of economic studies represents a 
second important gap in the evidence for current laboratory TB tests.  Examples of ‘cost-
effectiveness’ studies identified include: 
 
 rpoB test: this is estimated to cost ~£120/test, and £2,958 per MDR-TB case diagnosed.  
However, the test is 7 weeks faster than conventional culture [39]. 
 Direct amplification and reverse hybridization of the rpoB gene: this is reported to be 
‘cost-effective’ compared to indirect proportion method on Lowenstein-Jensen medium.  As 
would be expected, the method is reported to be most cost-effective in patient groups with a 
high prevalence of TB [25].  
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 Five different tests: the average cost per case detected has been estimated for a 2% 
prevalence of MDR-TB.  When transmission effects are included (e.g. savings due to lower 
transmission as a result of case detection), the cost per case detected ranges from US$ 3,031 
to US$ 8,672 in 2004 [25] or £2,252-£6,444 (2009 prices). 
 
In Table 2, a fairly conservative figure of £2,958 per MDR case detected is presented. 
 
3.2 Evidence on cost-effectiveness of tests used for screening 
 
New POC test should also be compared to existing tests in the context of screening, in addition to 
their potential use for detecting active disease in people presenting with symptoms.  The literature 
on cost-effectiveness of current TB tests used for screening and testing contacts mostly considers 
two types of test: the tuberculin skin test (TST) and the interferon-gamma test (IGT)/ 
interferon gamma release assay (IGRA).  IGRA/IGT has proved a useful addition for the 
diagnosis of dormant (or latent) TB infection in the absence of active disease.  However, the issue 
of latent infection, particularly among non-UK born people, remains a largely unaddressed source 
of future disease; there are no statistics providing a breakdown of LTBI cases identified in new 
entrants versus via contact tracing for people with infectious TB.   
 
There is currently no single, reliable test for detecting latent TB infection (LTBI).  Although TST is 
inexpensive (see Table 1) and relatively easy to perform, testing requires two patient visits which 
increases the overall cost to the NHS of this test.  Effectiveness is dependent on the patient returning 
within the specified time period for the second visit.  As pointed out above, the NICE guidelines 
recommend the use of the TST with positive test results followed by the IGT [12].  
 
The overall cost-effectiveness of any detection programme for LTBI is likely to be influenced 
particularly by levels of compliance with therapy once latent (or dormant) TB is detected.  At the 
same time, a 2008 systematic review of the literature has highlighted poor adherence to LTBI 
therapy [40].  The degree to which compliance levels are built into cost-effectiveness analyses 
varies.  The overall cost-effectiveness of any testing regime for LTBI will ultimately be dependent 
on the number of active TB cases prevented.   
 
The cost-effectiveness literature identified considers IGRA both as a replacement for, and as an 
add-on to, TST.  For England and Wales, economic modelling has indicated that a two-stage 
strategy (TST/IGT) will be cost-effective (£26,000 per QALY) for identifying LTBI in the context 
of a contact tracing programme, while TST and IGT on their own are not cost-effective methods 
[23].  Cost-effectiveness is reported to be higher in high incidence/ high risk populations.  Two 
systematic reviews of IGRA note excellent specificity for the tests to distinguish latent TB from 
prior vaccination [11, 41].  However, for detection of active TB infection, IGRA has reduced 
specificity due to its ability to detect latent TB [42].  
 
There is a lack of consistency in the manner in which ‘cost-effectiveness’ results are presented for 
TB screening/contact testing.  Studies also do not always distinguish active and latent TB findings.  
This variability once again made synthesis of the economic findings difficult.  Examples of findings 
reported include the following: 
 
 QuantiFERON-TB test: QFT-based screening programmes (with QFT as an add-on or 
replacement for TST) are both reported to provide superior clinical and economic outcomes 
in comparison to programmes based on TST alone in Germany, and at a ‘comparatively 
small additional cost’ [32].  The same authors subsequently reported that the cost of 
screening and treatment when using QFT alone amounted to €215.79 (£166.15) per close 
contact [43]. 
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 QuantiFERON-TB Gold test: the cost per positive case detected for QFT-G is reported as 
$US 171.78; compared to $US 145.99 using TST [32]; equivalent to £89.73 vs £76.25 
(2009 prices). 
 T-Spot.TB: TST followed by confirmation of positive results by T-Spot.TB test is reported 
to be the most cost-effective option for screening for latent TB infection in Switzerland 
[44].  More recently, Swiss researchers have suggested that TST should be replaced by the 
TIGRA test (T-cell interferon gamma release assays) [45]. 
 T-Spot.TB: more recent company material reports that use of T-SPOT.TB, either alone or 
in combination with TST, greatly reduces the number of contacts treated to prevent one TB 
case in [46]. 
 DHPLC: Denaturing high-performance liquid chromatography has been reported to be a 
‘cost-effective, rapid, sensitive, and high-throughput technique’ for TB screening [47]. 
 
Table 2 includes an estimated cost per ‘active case detected’ for screening/ contact testing (£5,442 
at 2009 prices). 
 
 
3.3 Evidence on screening of immigrants and refugees 
 
The cost analysis in section 2 excluded the cost of screening immigrants and refugees e.g. at port of 
entry.  However, surveys have consistently shown the highest rates of clinical TB disease in recent 
arrivals, particularly within the first few years after initial entry [23].  A recent UK epidemiological 
study has also identified that transmission within England accounts for only one in four cases, with 
the remainder arising from reactivation or acquisition outside England [48]. 
 
There is a mixed evidence base on the economics of screening immigrants and refugees.  As might 
be expected, screening overseas born children/adults is reported to be more cost-effective than 
screening all [49].  In low-incidence countries, screening of all migrants at port of entry using 
existing technology is thought to have little overall impact and not to be very cost-effective as a TB 
control strategy.  More efficient alternatives in this situation may include contact tracing delivered 
through primary care, as well as increased investment in global tuberculosis control [30].  Early UK 
research has indicated that contact tracing is more effective at detecting TB than new-entrant 
screening [50].  Findings from Canada also confirm that contact tracing is highly cost-effective, 
compared to immigrant TB screening at entry [51].  The 2011 NICE clinical guideline on new 
entrant screening suggests that as the prevalence of TB and the conversion rate of TB increase the 
tests (TST/IGT and IGT alone) will become cost-effective [15].  The UK Home Office and the 
Department of Health have piloted pre-entry TB screening in 8 countries. 
 
Recent NICE guidelines state that new entrants should be identified for TB screening [12].  
Research undertaken in the UK has estimated that screening individuals in general practice, new 
entrant clinics, and hostels for the homeless and would cost £1.26, £13.17 and £96.36 per person 
respectively, while the cost per person screened per case of tuberculosis prevented would be £6.32, 
£23.00, and £10.00 respectively [52].  In contrast, a more recent study of TB screening services for 
asylum seekers in one of the UK induction centres has reported that, although screening can achieve 
a high uptake, cost-effectiveness is questionable, particularly where the yield of active disease is 
low.  TST is not an ideal screening procedure in this setting because it may be uncompleted and the 
benefit of detecting latent infections is uncertain.  The annual cost of screening was estimated to be 
£350,000 [53].  Economic modelling also suggests that prophylaxis is not cost-effective in the 
context of new entrant screening [12]. 
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4  Overview of economic literature and improvements required in the UK 
 
There is very little published on the cost-effectiveness of existing tests for TB; this represents a 
major research gap.  In economic terms, rapid case detection, provision of drug therapy and 
ensuring completion of treatment are all important in reducing the burden associated with TB 
infection.  The question is – where in the system is it best to intervene for maximum economic 
benefit?   
 
In the UK context, a rapid POC test to screening contacts of TB patients to identify other active TB 
cases might provide benefits.  In particular, a more rapid test would be valuable since current tests 
can take up to 12 weeks.  The UK HTA Programme has commissioned research to assess the cost-
effectiveness of existing tests for rapid identification of active TB disease.  The study, which started 
in 2011, focuses on whole blood interferon-gamma enzyme-linked immunosorbent assay (ELISA) and 
enzyme-linked immunospot assay (ELISPOT) tests and is due to report in mid-2015 [54].  The cost-
effectiveness of other emerging tests e.g. Sequella TB Patch, also needs to be assessed before the 
cost-effectiveness of rapid POC technologies can be adequately considered for the UK. 
 
In economic terms, tests which offer increased speed of diagnosis are likely to have a direct cost 
saving in terms of people currently falsely suspected of having active TB.  Among these patients, a 
more rapid diagnosis ruling out TB will save money in terms of reducing unnecessary treatment 
costs and possibly improving contact tracing, although this is difficult to quantify.  However, speed 
of diagnosis is not necessarily the same as diagnostic turn-around time.  A recent systematic review 
of studies examining delays in diagnosis and treatment of TB has highlighted a ‘vicious cycle’ of 
repeated visits at the same healthcare level and failure to refer on to specialised TB services [55].  
Although earlier discharge of false positives and earlier correct treatment of TB cases will both 
improve cost-utility. 
 
Drug resistant TB remains a problem, particularly in London, and as our analysis indicates it incurs 
high treatment and mortality costs, although the latter could not be quantified.  Rapid, early 
indication of multiple drug resistance would enable clinicians to tailor drug therapy more 
accurately.  Improved cost-effectiveness should result from earlier correct treatment of atypical and 
drug-resistant TB. 
 
In the context of contact tracing, latent TB infection can currently be identified using a two-stage 
strategy (TST/IGT) with an incremental cost-effectiveness ratio of £26,000 per QALY; one of the 
few areas in which cost-utility data are available for existing TB tests.  Population programmes in 
the range £20,000-£30,000 are unlikely to be accepted by NICE on cost-effectiveness grounds 
alone.  In this case, cost-effectiveness will depend crucially on the prevalence within the population 
groups tested; 70 percent of LTBI cases are in non-UK born residents.  More importantly, there is 
currently no certain way of predicting which 10% of latently infected people will go on to 
present with active disease.  This will severely limit the cost-effectiveness of extending 
screening beyond the contact tracing context.  A test which is highly predictive of future 
development of disease would allow targeted chemoprophylaxis for individuals at risk of disease.  
The UK HTA Programme has commissioned research in this area which is due to report in early 
2016 [56].  Improved predictive performance may also help to address the underlying issue of poor 
adherence to LTBI therapy reported in a recent review [40].  If patients at particular risk of 
progression to active TB can be identified then adherence to prophylaxis may be improved through 
DOT-like approaches.  A recent Australian study has reported economic findings on the 
implementation of telecare technology as a cost saving device and to improve Directly Observed 
Therapy for TB [57] 
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General points which can be drawn from our overview of the literature include: 
 
 The current size of the market for different TB tests in the UK is unknown.  Consequently, 
it is difficult to estimate the economic impact of existing TB diagnostic and screening tests 
or the economic advantage of new tests. 
 
 Our analysis suggests that investment in the development of new diagnostic tests for TB is 
unlikely to offer significant cost savings for the UK healthcare system.  Tests currently 
available to diagnose active TB appear to demonstrate adequate performance, although the 
total cost of testing suspected TB cases could not be estimated with complete accuracy. 
 
 In order to establish the actual economics of TB detection in the UK, additional modelling 
of costs and benefits of system-wide diagnostic pathways (including imaging and laboratory 
tests for extra-pulmonary TB) would need to be undertaken.   
 
 The main problem in the UK appears to be late diagnosis of TB.  Earlier diagnosis would 
lead to fewer deaths and a lower number of cases per year, as active TB cases are diagnosed 
sooner and infect fewer healthy people.  From an economic perspective, it is important to 
identify whether cost or the poor performance of currently available tests influences this.  
There is no robust evidence that either the price of current tests or their performance 
significantly delays diagnosis.  However, the role of primary care in the referral process, 
and improvements in this area, are clearly also important.  Consideration of this was outside 
the scope of the current report. 
 
 Our conclusion from the available evidence is that the problem with TB diagnosis in the 
UK is systemic.  The key changes required are ones which will facilitate identification of 
TB cases as early as possible. 
 
 The major market for new TB tests will clearly be in high incidence countries in the 
developing world.  In this context, there is a need to introduce more cost-effective 
technologies which can test large populations at low costs. 
 
 While developing countries would benefit from high throughput new screening tests, low-
incidence countries such as the UK may be in need of more highly-specific diagnostic tests 
(e.g. MDR tests).  In some low-incidence countries, like the US, which have a significantly 
higher expenditure on TB than the UK, improvements in other diagnostic tests may prove to 
be an important tool to contain costs. 
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5  Estimating the economic benefits which new POC tests could provide 
 
5.1 Overview of economic analysis and model used 
 
Current testing scenarios (Table 3): 
Table 3 presents an overview of the UK status quo for TB screening and diagnostic tests (excluding 
chest X-rays).  Comparative data are provided for the technical performance (sensitivity/specificity) 
of tests currently used; times to result; and the setting where testing is currently undertaken.  The 
numbers of patients being tested annually is also presented (where this can be estimated).  The final 
two columns summarise current economic impact in the UK as detailed in section 2 above.  The 
penultimate column provides an estimate of the current laboratory cost of testing for suspected TB 
and screening costs associated with following contacts of active TB cases.  The final column lists 
annual costs associated with mortality, morbidity and NHS treatment of cases detected. 
 
New testing scenarios (Table 4): 
Table 4 presents the characteristics of an ‘ideal’ new test to replace the status quo sequential testing 
for suspected TB.  The Table includes information on test requirements (sensitivity/ specificity, 
time to result, and test process) for the new test. 
 
An economic model has been constructed to estimate the predicted economic benefits at national 
level of moving from the current status quo to implementation of a new test. 
 
The economic model: 
A relatively simple cost model was constructed in Excel to estimate national level costs for TB 
diagnosis following a referral for suspected disease in the two scenarios presented in Table 3 
(status quo) and Table 4 (new test).  This analysis excluded tests for screening/ detection of 
latent TB infections, for which accurate national level test data could not be identified. 
 
Data in the model: 
The model parameters were based on the highest level of evidence available from our review of the 
literature, and through contacting experts. 
 
The main economic drivers for the new diagnostic tests were assumed to be changes in the number 
of false negatives/false positives and increases in the number of true positives detected.  These in 
their turn were assumed to impact on the number of infections transmitted and on mortality. 
 
The impact on morbidity could not quantified due to lack of robust data (e.g. QALYs), and was not 
included in the model. 
 
Costs: 
For each testing scenario, we estimated the number of cases of detected/ undetected and 
treated/ untreated infections and subsequent direct cost consequences.  Indirect and intangible 
costs associated with TB infections, including lost time from work, pain, anxiety, and morbidity 
were not included in the analysis.  Thus, the results presented below are likely to be an 
underestimate. 
 
5.2 Overview of economic results 
 
The current pattern and sequence of testing (status quo) for detection and antibiotic susceptibility 
testing was assumed to involve 3 samples per person and the following sequence: (i) all 3 samples 
undergo sputum smear (microscopy) test and liquid culture; (ii) 1 sample undergoes standard solid 
culture; (iii) 1 NAAT test or gene probe MTBC is carried out per person to confirm culture positive 
samples for MTB; (iv) all positive MTB samples undergo further test to screen for antibiotic 
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susceptibility.  For the new single-step test, it is assumed that the same number of people will be 
tested. 
 
For cost modelling purposes it was assumed that the ideal new test would cost (per person tested) 
the same as the current combination of laboratory tests.  Comparison of the costs and financial 
benefits of the two scenarios, status quo (Table 3) versus new test (Table 4), was undertaken.  For 
the current system, in the economic model, significant losses were associated with a high number of 
false negatives which lead to increased mortality (maximum potential loss estimated at ~£30 
million) and additional infections (potential losses up to £0.1million).  The characteristics of an 
ideal new test will result in (i) fewer steps; (ii) improved sensitivity i.e. more cases accurately 
detected (model not actual); and (iii) a more rapid test result. 
 
In terms of improved sensitivity, the cost model indicated that additional cases detected will lead to 
extra treatment costs (~£11 million) in year 1, compared to the status quo scenario.  However, a 
financial benefit will be realised from a significantly lower number of false negatives resulting in a 
decrease in deaths from TB (modelled losses due to death amount to £0.14million).  
 
The reduced turn-around time for a diagnostic result (from 4-6 weeks for culture to <2 hr for new 
Point of Care (PoC) test) may provide an additional benefit in economic terms.  However, in the 
current model, it was not possible to quantify this benefit in financial terms.  Although, the low TB 
infectivity rate means that there will be relatively little impact on the overall number of infections 
and therefore associated costs, a saving linked to speedier diagnosis could be reduced expenditure 
on contact tracing.  This will only occur if contact tracing is currently initiated before culture and 
NAAT test results are available.  In this case, a more rapid test would limit contact tracing to the 
36% of cases that are positive which could add a further saving of £0.5 million per annum
8
. 
 
Comparison of the two scenarios predicts an annual saving of ~£18 million following replacement 
of the status quo with a single new test with high sensitivity and specificity (98/98).  Although a 
break-even test cost could not be calculated, any new test should probably not be more expensive 
than the current cost of laboratory testing (combination of tests).  This is an average £118 per 
referral. 
 
It should be remembered, however, that TB transmission within the UK may account for only a 
quarter of total cases, with the remainder arising from reactivation or acquisition outside the 
country.  This emphasises the importance of considering new test development in the screening 
context, as well as for laboratory diagnosis.  Additional data would need to be acquired in order to 
be able to model the economic benefits of new POC technology in this broader context. 
 
 
                                            
8
 Further potential savings on screening of contacts is not included here as it is not clear whether the new test 
will impact the number of LTBI cases that are being screened annually.  
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TABLE 1:  TB – Published Unit Test Costs (All costs are converted to 2009 GBP) 
 
 
Diagnosis of 
 
Test name 
 
Cost/test (£) 
(consumables only) 
 
Cost/test (£) 
(total) 
 
Source(s) 
Active/Latent 
TB 
    
 
 
 
Tuberculin Skin Test 
(TST) 
 16.44 [27] 
 Interferon – gamma 
test (QFT-G) 
 
 50 [27] 
 
 
 
Standard Culture test 7.31 16.70 [11] 
 Liquid Culture test  27.16 [11] 
 Acid-Fast 
Microscopy 
 
Auramin/Acridine 
orange commercial 
kit 
 
Fluorochrome 
method 
 
 
 
11.19 /100 slides 
 
13.02/100 slides 
 
~0.36 
[58] 
 GenoType 
Mycobacteria Direct 
assay 
 
36.56-69.46 
 [59] 
 GenProbe AMTD  
 
 
29.25-58.50 
 
 [11] 
 BACTEC 9000  6.51/analysis [60] 
 Blood agar  1.39/analysis [60] 
 
 
RT-LAMP-ELISA 6.27  [38] 
 
 
TaqMan RT-PCR 7.52  [38] 
 
 
AMTD 31.34  [38] 
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Diagnosis of… 
 
Test name 
 
Cost/test (£) 
(consumables only) 
 
 
Cost/test (£) 
(total) 
 
 
Source(s) 
Multiple drug 
resistance 
    
 
 
rpoB sequencing  125.35 [39] 
 DHPLC 0.63 
 
 [47] 
 PCR-RFLP 
(Isoniazid only) 
0.94  [61] 
 
 
NAAT commercial 
kit 
15.67-31.34  [62] 
 
 
IDLJ 25.07 (23.19)*  [25] 
 FASTPlaque-
Response 
25.91  [25] 
 
 
INNO-Lipa 69.99  [25] 
 
 
DLJ 19.01 (15.67)  [25] 
 
 
MTT assay 22.25 (19.08)  [25] 
  Detection 4 drugs 
susceptibility 
  
 
 
MODS 0.48 1.13  [63] 
 
 
MGIT 
4.39 39.51 
 [63] 
 
 
BACTEC 
1.60 14.41 
 [63] 
 
 
LJ 
0.08 0.98 
 [63] 
 
 
Microagar 7H11 
0.18 1.83 
 [63] 
 
 
MABA 
0.77 4.30 
 [63] 
 
 
PCR 
1.82 
  [63] 
 
 
Acid-fast stain 
smear 0.06 
  [63] 
 
* In brackets rimfapicin only cost  
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TABLE 2:  Tuberculosis Economic Summary for the UK (2009) 
 
 
 
 
 
 
 
 
 
 
 
Number of 
cases (2009) 
 
 
 
 
Cost/patient tested 
(£) 
 
 
 
Cost per case detected 
 
 
 
 
 
Cost per case treated  
(£) 
Active TB  
 
 
9,040 
 
£252
1
 
 
£91- £3,497
2
 
 
~£3,300
3
 
Multiple drug 
resistant TB  
 
 
58 
 
N/A
4
 
 
£2,958 
 
£75,510 
Contact tracing 
 
 
58,760 
 
£23 
 
 
£5,442
 5
 
N/A 
Latent TB 
infection 
 
 
17,040  
 
£24.2 
 
£647 [22] 
 
N/A Not available 
1
  Includes cost of X-rays & antibiotic susceptibility testing 
2
  Published cost/ active TB case detection varies widely;  international figures will depend on the type of test used & TB incidence in population  tested.  No cost-utility data reported. 
3
  Includes standard treatment including Directly Observed Therapy (DOT), hospitalisation and outpatient costs  
4
  Antibiotic susceptibility testing is provided for all active TB cases and included in the above figure. 
5
  Cost of tracing (£1.35 million) and further diagnosis (1.85 million) per active case detected (1% of 58,760 contacts) 
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TABLE 3:  Overview and summary of current tests for screening and diagnosing active TB cases 
 
Test Type Current UK test context Current tests used Current test capability 
Current economic 
impact 
 
Number of 
UK patients 
tested 
annually 
Settings 
where tests 
undertaken 
Type of 
tests 
used 
Test process Type of 
specimen 
Time to 
perform 
test/ 
result 
Sensitivity/ 
Specificity 
 
Annual lab 
testing 
Cost 
 
Annual 
Burden of 
disease  
Host 
response 
NA POC TST 
2 visits. If 
negative repeat 
in 1-3 weeks 
NA 
Result 48 
and 72h 
77/97 Non-
vaccinated 
77/59 BCG 
Vaccinated [64] 
£1.85 
million 
Mortality:  
£99 million 
 
Morbidity:  
£40.7million 
 
NHS 
treatment/ 
care costs: 
£45 million 
 
Host 
response 
NA 
Use after 
positive skin 
test 
IGRA 
Enzyme linked 
assay 
Blood ~24h 95/97 [11]   
Microscopy 35,200
1
 Laboratory 
Sputum 
Smear 
Slides stained 
and examined. 
Then requires 
confirmation 
using culture. 
Sputum ~24h 
31-98/95-100 
[65]   
£4.44 
million
2
 Culture 35,200 Laboratory Culture 
Culture, which 
then requires 
confirmation as 
MTB. 
Multiple 
Solid 
media 4-6 
wk 
Liquid 
media 
>12d 
Solid media 
98/NA 
Liquid media 
91/NA 
Molecular 11,981
3
 Laboratory NAAT 
Confirmation of 
culture positive 
samples for MTB 
Culture 3-6h 73/94 [11] 
1
  Patients referred with suspected TB (excludes screening) 
2
  Excludes annual cost of screening tests (N/A), chest X-ray, primary care visits, and contact tracing  
3
  Based on ‘cases’ identified by culture stage (True positives + False positives)
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TABLE 3 (contd):  Overview and summary of current tests for screening and diagnosing active TB cases 
 
Test                                                                                                                                                                           
Type 
Current UK test context Current tests used Current test capability 
Current economic 
impact 
Number of 
UK patients 
tested 
 
Settings 
where tests 
undertaken 
Type of tests 
used 
Test 
process 
Type of 
specimen 
Time to 
perform 
test/result 
Sensitivity/ 
Specificity 
 
Annual lab 
testing 
cost 
 
Annual 
Burden of 
disease  
MDR 
Only culture 
positives will 
be screened 
for antibiotic 
susceptibility 
Laboratory 
Solid-phase 
hybridization* 
Genetic 
resistance 
markers 
Multiple <2h - 2d 95†/98 
Included in 
figures 
above 
Included in 
figures 
above 
MDR As above Laboratory 
Radiometric 
systems** 
Genetic 
resistance 
markers 
Culture 
samples or 
smear +ve 
patient 
material 
6-12d 97/100 
MDR As above Laboratory 
Phage-based 
assay‡ 
Sample 
infected 
with 
phages 
Respiratory 1d NA 
 
* e.g. INNO LiPA, GenoType MTBDR; ** e.g. BACTEC † smear positive samples ‡e.g. In house assays, FastPlaque TB 
1
  Excludes annual cost of screening tests (N/A), chest X-ray, primary care visits, and contact tracing  
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TABLE 4:  Predicted likely economic benefits of new test for diagnosing active TB and MDR cases 
 
 
 
 
 
Main driver(s) for 
technology development 
 
New test 
UK role 
 
Target population/  
sub-population 
 Ideal new test requirement Predicted economics of new test  
 
Target 
population 
to be tested 
 
Number 
of UK 
patients 
 
Time to 
result (hrs) 
 
Sensitivity/ 
Specificity 
 
Setting for 
test 
 
 
Test 
process 
 
Break-even 
Test Cost 
 
 
Annual 
Cost saving
3
 
 Current diagnosis of 
MTB and MDRTB is a 
multi-step process 
taking place over a 
prolonged time period. 
 Decreased time to 
diagnosis will aid in 
more rapid contact 
tracing. 
 Will limit transmission & 
enable more patients to 
commence appropriate 
treatment earlier. 
 
Detection 
and 
screening 
Community/ 
Hospital 
(suspected 
TB) 
35,200
1
 <1h 98/98 POC/ 
Rapid lab 
Single step  
N/A
2
 
 
 
 ~£18 million 
1
  Patients referred with suspected TB (excludes screening & contact  tracing) 
2
  Model assumes that the new test cost is comparable to the combination of current tests 
3
  It is assumed that the new test costs the same as current laboratory testing (combination of microscopy, culture and NAAT). 
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Annex 1:  TB Treatment and Diagnosis Cost Estimates: Input parameters and assumptions 
 
TREATMENT Source Unit cost/ number Total annual cost (UK) Comment 
Standard drug therapy   £1.63 million  
 [11] £210 per case x 7,788 (non MDR, non DOT 
TB cases) 
£1.63million HTA review unit price 
DOT therapy   £1.37  million  
 [66] DOT 814 x £300 
(Assume 10% of UK not HTR cases) 
DOT HTR: 380*£2,964 
(Assume ~42% of hard to reach cases in UK) 
£0.24 million 
 
£1.13 million 
 HTR = hard to reach 
Multi-drug resistant TB   £4.38 million  
 [23] 
[19]  
58 cases in UK 2009 
£75,510  per base case 
 
 
£4.38 million  
 
. 
Non-elective inpatient episodes   £19.0 million  
 [11] ~56% of patients are hospitalised 
Non-HTR cases 4,527*£3,386 
HTR cases 503*£7,320 
£19 million  
Outpatient/    £7.60 million  
 [15] £921 x 8,254 outpatients 
(Assume ~90% UK cases) 
£7.6million  
Latent TB*   £11.0 million  
 [12] 
[22] 
17,040 of TST positive cases (in which no 
active TB is identified) *£647 
11million  
TOTAL TREATMENT   £45.0 million  
*Assumed Latent TB treatment is provided only for TST positive cases. 
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DIAGNOSIS Source Unit cost/ number Total annual cost (UK) Comment 
X-rays: diagnostic   £1.31 million  
 NHS reference 
cost 
[14] 
Chest X-rays @ £28 
Assumed 35,200 patients  
Mobile Xray @ £16 on 20,000 HTR and 
prison population 
£0.99 million 
 
 
£0.32 million 
  
Lab tests: suspected TB
9
   £4.44 million   
 [12, 22] Assumed all 3 samples have sputum 
smear (microscopy) = 3x1.5x35,200 
patients 
£0.16 million  
 [11] Assumed 3 samples have liquid + 1 
standard culture) @ (£27.17x3 + £16.71) 
=  £98 per case x 35,200 patients 
£3.46 million HTA review prices 
 [11] NAAT test or gene probe MTBC @ 
£15.67 per case x 11,981 patients 
£0.19 million HTA review prices 
 [63] Susceptibility testing (4 drugs) @ 
£7. 
Assumed 9,040 patients tested 
£0.63 million Literature price [25] uplifted to 
2009 
Primary care visits   £2.52million  
  Assumed 1 GP surgery consultation prior 
to referral & second following test results 
@ £36 x 2  x 35,200 patients 
£2.52 million 2009 PSSRU prices 
Contact tracing   £1.35 million  
 [12] £23 per contact x 58,760 £1.35 million  
Latent TB*   £1.85 million  
 [27] TST test for all contacts: 58,760*£16.44 
IGRA test only for positive TST: 
17,628*£50 
£0.97 million 
£0.88million 
 
TOTAL DIAGNOSIS (INCL. 
CONTACT TRACING) 
  £11.47 million 
 
 
TOTAL: DIAGNOSIS & 
TREATMENT 
  £56.47 million 
 
 
*Assumed only traced contacts are tested for Latent TB infection. 
 
                                            
9 Tuberculosis prevention and treatment: a toolkit for planning, commissioning & delivering high-quality services in England- DH - TB Action Plan Team June 2007 
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